What is ENSEM Therapeutics?
Headquartered in Boston, MA, ENSEM Therapeutics is a biotechnology firm dedicated to advancing oncology targets. The company's focus on critical areas within cancer research positions it as a key player in the development of novel therapeutic strategies. Its enterprise-level funding suggests a mature stage of development, likely focused on scaling operations and advancing its pipeline through clinical trials.
How much funding has ENSEM Therapeutics raised?
ENSEM Therapeutics has raised a total of $67M across 1 funding round:
Series A
$67M
Series A (2022): $67M with participation from GGV Capital, CBC Group, Pavilion Capital, Mitsui & Co., and Cenova Capital
Key Investors in ENSEM Therapeutics
GGV Capital
GGV Capital is a global venture firm investing in early-stage to growth-stage companies across Social/Internet, Enterprise Tech, and Smart Tech sectors.
Pavilion Capital
Pavilion Capital Partners is a growth-oriented private equity investor focused on fast-growing companies in the United States and Asia, particularly in industries driven by globalization and technology.
Mitsui & Co.
Mitsui & Co. is a global trading and investment company with a diverse portfolio across multiple industries, focused on creating long-term sustainable value through strategic initiatives and partnerships.
What's next for ENSEM Therapeutics?
With substantial enterprise-level backing, ENSEM Therapeutics is poised for significant growth and pipeline advancement. The recent strategic investment signals strong investor confidence, likely enabling the company to accelerate its research and development efforts, expand its team, and potentially pursue strategic partnerships or acquisitions. The focus will likely be on translating its innovative oncology targets into viable clinical treatments, aiming to make a substantial impact on patient outcomes.
See full ENSEM Therapeutics company page
